suggest that CBP/p300 may play a distinct role in trana nonspecific interaction between p53 and [ 14 C]-acetylCoA or p53 autoacetylation. scriptional regulation through histone acetylation.
Acetylated histones are a characteristic feature of Furthermore, by measuring [ 14 C]-acetate incorporation in a filter binding assay , we transcriptionally active chromatin. Hyperacetylated histones accumulate within particular active chromatin donot only confirmed that p53 can be acetylated by p300, but also that the acetylation of p53 is as strong as the mains, whereas hypoacetylated histones accumulate within transcriptionally silenced domains (reviewed in acetylation of core histones by p300 under the same conditions ( Figure 1C) . Thus, we have demonstrated Turner, 1993; Brownell and Allis, 1996; Wolffe and Pruss, 1996) . Thus far, all core histone proteins can be variably that p53 is a novel, and genuine, substrate for the p300 acetyltransferase in vitro. acetylated by a number of proteins, designated histone acetyltransferases (HATs) , that include GCN5, P/CAF, p300/CBP, and TAFII250 (Bannister and Kouzarides, The p53 Site Acetylated by p300 Is Located at the 1996; Kuo et al., 1996; Mizzen et al., 1996; Ogryzko et al., C-Terminal DNA-Binding Regulatory Domain 1996; Yang et al., 1996) . Importantly, a global increase in
The p53 protein can be roughly divided into three distinct core histone acetylation does not necessarily induce functional domains (Ko and Prives, 1996) : an aminowidespread transcription. In some instances, an interminal domain that contains the transcriptional activacrease in histone acetylation correlated with a decrease tion domain (residues 1-43), a central core that contains in transcriptional activity (reviewed in Pazin and Kadothe sequence-specific DNA-binding domain (residues naga, 1997), suggesting that the relation between acetyl-100-300), and the multifunctional carboxy-terminal dotransferase function and transcriptional activity may be main (residues 300-393) ( Figure 2A ). To map the more complex than a matter of histone acetylation and p300-dependent acetylation site of p53 in vitro, GSTconsequent transcriptional activation. Indeed, the posp53(1-73), , and GST-p53(290-393) sibility that these acetyltransferase activities might have fusion proteins were expressed in bacteria and purified other protein substrates has not been reported.
to near homogeneity on glutathione-agarose beads (FigIn support of this possibility, we demonstrate that ure 2D). As indicated in Figure 2B , only GST-p53(290-p300 can directly modify the C-terminal domain of p53 393) was detectably acetylated by p300, suggesting that by acetylation and, remarkably, that this modification the acetylation site is located in the C-terminal domain. not only is position-specific, but also dramatically stimuThe p53 carboxyl terminus can be further subdivided lates the sequence-specific DNA-binding activity of p53.
into three regions, which include ( Figure 2A ) a flexible This discovery has important implications for current linker (residues 300-320) that connects the DNA-binding views regarding the molecular mechanisms by which domain to the tetramerization domain, the tetramerizaacetyltransferase-containing coactivators effect trantion domain itself (residues 320-360), and, at the exscriptional activation.
treme carboxyl terminus, a 30 amino acid stretch that plays a very important role in the regulation of p53 DNA binding (residues 363-393). Purified GST fusion proteins Results containing these subdomains ( Figure 2E ) were tested for acetylation by p300. Although each subdomain contains Identification of p53 as a Bona Fide Substrate several lysines, which are potential acetylation sites for for p300 Acetyltransferase acetyltransferases, only the C-terminal 30 amino acid To test whether p53 could be specifically acetylated domain was acetylated ( Figure 2C ). by p300, the following proteins were expressed with N-terminal Flag epitopes in bacteria and purified to near homogeneity on M2-agarose affinity columns: a region p53 Is Acetylated In Vivo p53 is a short-lived protein that is maintained at low, of p300 (residues 1195-1810) containing the HAT domain , full-length p53 (Gu et al., often undetectable, levels in normal cells (Ko and Prives, 1996) . Compared with histones, it is extremely difficult 1997), Max (Blackwood and Eisenman, 1991) , USF (USF-1) (Gregor et al., 1990) , and the p300/CBP-interto purify sufficient p53 protein from normal cells to test whether acetylated p53 exists in vivo. Furthermore, acting CREB (Chrivia et al., 1993) . These highly purified recombinant proteins were used in the protein acetyloverexpression of wild-type p53 induces apoptosis in many cell types, thus making it impossible to obtain transferase assay to avoid possible contamination by either histones or other acetyltransferases.
p53-stably transfected cell lines for this purpose. Here, we tested whether p53 is acetylated in tranIndividual reactions containing 1 g of each substrate were incubated with [
14 C]-acetyl-CoA and 100 ng of resiently transfected cells. As indicated in Figure 3A , p53 can be transiently overexpressed shortly after transfeccombinant p300 for 1 hr at 30ЊC. The products were analyzed by autoradiography of acetylated reaction tion ( Figure 3A , lane 2). These cells were immediately labeled by [ 3 H]-sodium acetate (1 mci/ml) for only 1 hr products resolved on SDS-PAGE gels. As shown in Figure 1A , the p53 protein was specifically labeled by to limit the protein labeling to posttranslational modifications. Figure 3B shows that the p53 protein immunopuri-[ 14 C]-acetyl-CoA, whereas no signals were detected in reactions containing USF, Max, or CREB. Labeling of fied under very high stringency conditions (see Experimental Procedures) by anti-p53 monoclonal antibody p53 was completely dependent on the presence of both was detected either in proteins affinity-purified from the residues in vivo (Hendzel et al., 1991; Kijima et al., 1993; Vettese-Dadey et al., 1996) and, to date, has limited same extract by anti-hemagglutinin (HA) control antibody ( Figure 3B Recent studies have demonstrated position-specific acetylation of histone H4 by distinct acetyltransferases acids of the protein (Crook et al., 1994; Marston et al., 1994) , is expressed at comparable levels in the cells by (Brownell and Allis, 1996) . Thus, while cytoplasmic acetyltransferases for histone deposition and chromatin transient transfection ( Figure 3A, lane 3) ; however, the signal of acetylated p53⌬370, purified by the same assembly modify positions 5 and 12, the transcriptional coactivator GCN5 preferentially modifies positions 8 method as acetylated wild-type p53, is significantly reduced ( Figure 3B , lane 3), suggesting that the C terminus and 16 (Kuo et al., 1996) . To similarly determine the positions of p53 acetylated by p300, a synthetic peptide of p53 may be mainly responsible for p53 acetylation in vivo. This also provides evidence indicative of similar that contains the carboxy-terminal 26 amino acids was incubated with p300 and [ 14 C]-acetyl-CoA. The acesites of acetylation in vivo and in vitro.
Taken together, these results indicate that p53 is intylated peptide was purified and subjected to aminoterminal peptide sequencing. The amount of [ 14 C]-acedeed acetylated in vivo. However, under the conditions employed, the proportion of acetylated p53 remains low.
tate incorporated in each residue indicated the degree of acetylation of this residue. As shown in Figure 4A , the This may reflect the action of strong deacetylase activities during the purification or rapid turnover of the acetyl [ 14 C]-acetate incorporation levels for various positions (A) shows schematic representations of p53 and its functional domains. The p53 fragments indicated (A) were expressed as GST fusion proteins, purified to near homogeneity, and analyzed by resolution on SDS-PAGE gel and Coomassie blue staining (D and E). Corresponding GST fusion proteins (2.5 g) were assayed for acetylation by p300 as described in Figure 1A , with reaction products analyzed by SDS-PAGE and autoradiography (B and C).
indicate two peaks located at K373 and K382, respecdue to the specific experimental approach . We find that five lysines of p53 (K370, K372, tively, suggesting that these two lysines are preferentially acetylated. Lysines K370, K372, and K381 also K373, K381, and K382) can be acetylated by p300 ( Figure  4B ), and that K373 and K382 are preferentially acetylated showed significant, but lower, levels of acetylation, whereas K386 appeared completely unacetylated in on the basis of the incorporated [ 14 C]-acetate activities. In comparison with the acetylated sites identified from comparison with the background. These results indicate that p53 acetylation is highly position-specific. the GCN5-mediated acetylation of histone H4 by a similar approach (Kuo et al., 1996) , we note that both the p53 is an evolutionarily conserved protein, particularly among vertebrate species (Soussi et al., 1990) . There is pattern and the position of the preferentially acetylated lysines are very similar ( Figure 4C ). Taken together, one conserved region in the amino-terminal activation domain, and there are four conserved regions in the these results indicate that the acetylation site of p53 is not only specific, but also evolutionarily conserved. sequence-specific DNA-binding domain, while no conserved region has been found in the C terminus (Soussi et al., 1990; Ko and Prives, 1996) . Surprisingly, a comparison of the acetylation site of human p53 with the Acetylation of p53 Activates Its Sequence-Specific DNA Binding same region from other vertebrates reveals that the positions of all of the acetylated lysines are highly con-A number of studies indicate that the C-terminal 30 amino acids of p53 play a key role in the regulation of served, including K370, K372, K373, K381, and K382 ( Figure 4B ), whereas the nonacetylated K386 is not consequence-specific DNA binding by p53 (Hupp et al., 1992; Hupp and Lane, 1994; Meek, 1994 ; Jayaraman served ( Figure 4B ). These results suggest that p53 modifications by acetylation may remain highly conserved and Prives, 1995). Since the acetylation site was mapped to this domain, it was important to examine the effect throughout evolution. Interestingly, an arginine (R379) and its position are also highly conserved, indicating of acetylation on site-specific DNA binding by p53. To exclude the possibility that other modifications, such as that besides lysine, arginine may also play a role in acetylation.
phosphorylation (Meek, 1994) or glycosylation (Shaw et al., 1996) , may interfere with this effect, we used highly p300 can acetylate all four N-terminal lysines (K5, K8, K12, and K16) in histone H4. However, differential acepurified, bacterially produced full-length human p53 in this assay. As reported previously (Hupp et al., 1992) , tylation of these sites has not been observed, perhaps 6), which nonetheless recognizes the whole p53/DNA complex, and other control monoclonal antibodies (Figure 5A, lanes 3 and 4) . Surprisingly, a dose response analysis showed that a 200-fold molar excess of an unlabeled oligonucleotide containing the wild-type p53 binding site but not by acetylation by p300 in vitro could dramatically increase the DNA-binding activity of fixed amounts of p53 (Figure comparable amounts of an oligonucleotide containing a mutated binding site ( Figure 5D , lanes 4-6). 5B). As indicated in Figure 5C , activation of the DNA binding by acetylation reached levels as high as 20-to Interestingly, the acetylated form of p53 was supershifted both by anti-p53 monoclonal antibody PAb421 30-fold over untreated p53 binding. No change in DNAbinding activity was found after treatment of p53 with (epitope in the C-terminal domain of p53) and by antip53 monoclonal antibody DO-1 (epitope in the N-termiacetyl-CoA or p300(1195-1810) alone ( Figure 5D , lanes 1-3), indicating that the stimulation of DNA binding is nal domain of p53) ( Figure 4D , lanes 8 and 9), similar to what was observed with the unmodified form (Figure specifically due to the acetylation of p53. Furthermore, the strongly enhanced DNA-binding activity of p53 is 4A, lanes 5 and 6). Whereas DO-1 did not enhance binding either of acetylated p53 ( Figure 4D ) or unmodified sequence-specific since the binding was competed by p53 ( Figure 4A ), PAb421 did enhance binding of aceactivate p53 DNA binding. To further confirm this hypothesis, we tested the effect of acetylation on the ability tylated p53 ( Figure 4D ). However, this latter effect was minimal (‫-2ف‬fold) compared to the very large effect (over of the C-terminal peptide to activate p53 in trans. As shown in Figure 6A , the unmodified form of the synthetic 20-fold) of PAb421 on DNA binding by the unmodified p53 ( Figure 4A ). This suggests that activation by antipeptide derived from the C terminus strongly activated (up to 7.8-fold) the DNA-binding capability of the fullp53 antibody PAb421 and activation by acetylation may involve similar molecular mechanisms. length p53 ( Figure 6B ), whereas the acetylation of the C-terminal peptide significantly (‫-2ف‬fold) reduced its ability to activate p53 in the same assay (Figures 6A and Insight into the Mechanism of Acetylation-Mediated Activation 6B). This result suggests that the acetylated C-terminal peptide has a reduced ability to interact with the core The specificity of the effect of the p53 C terminus on p53 sequence-specific DNA binding suggested that there domain and thus is less active in stimulating DNA binding of the full-length p53 in trans. might be intramolecular interactions between the C terminus and the central core domain (Hupp et al., 1995;  Interestingly, previous studies indicated that substitution of any of the five lysines (K370, K372, K373, K381, Jayaraman and Prives, 1995). It has been proposed that this interaction locks the core into a conformation that and K382) with alanine dramatically reduces the ability of the synthetic C-terminal peptide to activate p53 in is inactive for DNA binding and that the core is then able to adopt the active form when this tail-core interaction trans (Hupp et al., 1995) . This is completely consistent with our discovery that acetylation of these five lysines is disrupted by phosphorylation, antibody binding, or deletion (Hupp and Lane, 1994; Ko and Prives, 1996) .
reduces the ability of the C-terminal peptide to activate p53 in trans. In addition, there appears to be a competitive disruption of this interaction by synthetic C-terminal peptides that can activate p53 in trans (Hupp et al., 1995; Jayaraman Discussion and Prives, 1995) .
The acetylation by p300 of these lysines in the C termip300/CBP has emerged as a transcriptional coactivator for a broad group of cellular DNA-binding regulatory nus of p53 leads to a neutralization of positive charges that in turn could disrupt the tail-core interaction and proteins (reviewed in Shikama et al., 1997) , including the suppress cell proliferation, to the associated effect on cell growth. Our discovery is also of special interest in relation to current models regarding the mechanism of transcriptional activation by a number of coactivators (including p300) with histone acetyltransferase activity, the assumption having been that histone modifications play the major (if not exclusive) role in the function of these coactivators.
Activation of p53 by Acetylation
Transactivation by p53 is tightly regulated in vivo and correlates well with its binding to cognate DNA sequence elements (El-Deiry et al., 1992; Funk et al., 1992; Hansen and Oren, 1997) . Most oncogenic mutants of p53 have lost their ability to function effectively in a sequence-specific DNA-binding manner, suggesting that these activities of p53 are critical for its tumor suppressor function. Furthermore, considerable evidence indicates that posttranslational modifications of the carboxyl terminus of p53 play a key role in converting p53 from an inert to an active form for DNA binding (Ko and Prives, 1996) . The specific mechanisms involved in p53 latency and activation after posttranslational modification remain unclear. According to the allosteric model (Hupp et al., 1992 (Hupp et al., , 1995 Jayaraman and Prives, 1995) , the C-terminal tail of p53 interacts with the core DNA-binding domain and locks the DNA-binding domain into an inactive conformation. Significant in this regard is our demonstration of p300-mediated acetylation of specific lysine residues in the C terminus of p53, with a consequent activation of DNA binding. The acetylation-mediated neutralization of positive charge could disrupt interactions between the C-terminal domain and the core domain, thus allowing the DNA-binding domain to adopt an active simply by competitive disruption of the core-tail interacIn lane 6, 25 ng of p53 was incubated with the probe in the presence tion, whereas the acetylated form that lacks the positive of 0.50 nmol of the p53 C-terminal peptide (364-389) and 10 ng of p300(1195-1810), indicating that contaminating p300 charges would also lack the ability to fully activate p53 from acetylated p53(364-389) has no effect on p53 DNA binding.
in trans. Interestingly, the proposed role of acetylation Mohammadi et al., 1996) .
were quantitated by phosphorimaging using Image-Quant software, and representive results depict the average of three experiments
The ability to activate the p53-mediated transcripwith standard deviations indicated.
tional function both in vitro and in vivo, by interaction either with monoclonal antibody PAb421 (Hupp et al., 1995) or with C-terminal peptides (Selivanova et al., tumor suppressor p53 (Gu et al., 1997; Lill et al., 1997) . 1997), underscores the rate-limiting nature of the seFollowing our earlier demonstration that p53 functions quence-specific DNA binding in p53 activation. These synergistically with p300/CBP, we show here: (i) that findings also suggest the presence of a cellular pool p53 is a substrate for the acetyltransferase activity of of latent p53 that can be activated posttranslationally. p300; (ii) that acetylation of p53 is restricted to the C Serine phosphorylation of the carboxyl terminus has terminus and activates the latent sequence-specific also been shown to stimulate the DNA binding of p53 DNA-binding activity of p53; (iii) that p53 is acetylated in vitro (Hupp et al., 1992; Meek, 1994) . However, elimiin vivo, as well as in vitro; and (iv) that residues in the nation of one phosphorylation site (serine 386 in mouse acetylation site are evolutionary conserved. These rep53 or serine 392 in human p53) by alanine substitution sults are especially relevant to the in vivo transcription had no significant influence on p53-dependent transfunction of p53 and, since sequence-specific transcriptional activation by p53 correlates well with its ability to activation in cells (Fiscella et al., 1994; Hall et al., 1996) , Full-length p53 exists in a latent DNA-binding form as result of the tail-core interactions, as suggested by several studies (Hupp et al., 1992; Hupp et al., 1995; Jayaraman and Prives, 1995) . Acetylation of lysine residues in the C-terminal region results in neutralization of positive charges and leads to the disruption of interactions between the C-terminal domain and the core domain, thus allowing the DNA-binding domain to adopt an active conformation. Competitive disruption of this tail-core interaction by synthetic C-terminal peptides can also activate the DNA binding of the full-length p53 (Hupp et al., 1995; Jayaraman and Prives, 1995) . However, when the positive charges in the C-terminal peptides are neutralized by acetylation, the acetylated peptide loses the ability to activate p53 DNA binding in trans.
raising the question of whether this type of phosporylaand Kouzarides, 1996; Ogryzko et al., 1996) , P/CAF , and TAFII250 (Mizzen et al., 1996) tion is functional in vivo. It is possible that the effects of other activation pathways (e.g., acetylation) may were shown to possess intrinsic HAT activities. Similarly, mask this effect in vivo.
various yeast and mammalian corepressors were impliCompared with antibody PAb421 binding, addition of cated as, or shown to interact with, proteins that have C-terminal peptides, and phosphorylation, activation of intrinsic histone deacetylase activities (Alland et al., p53 by acetylation may be more physiologically relevant.
1997; Hassig et al., 1997; Heinzel et al., 1997 ; Kadosh This is supported by our previous observations that and Struhl, 1997; Laherty et al., 1997; Nagy et al., 1997 ; p300/CBP strongly interacts with p53, both in vivo and Zhang et al., 1997) . Histone acetylation can result in in vitro, and potentiates p53-mediated transcriptional nucleosome destabilization and chromatin remodeling activation in cells (Gu et al., 1997; Lill et al., 1997) . Fur- (Turner, 1993; Brownell and Allis, 1996 ; Wolffe and thermore, the present study shows that residues in the Pruss, 1996), which is likely important for accessibility acetylation site are evolutionarily conserved and, imporand/or stable binding of transcription factors to cognate tantly, that p53 is also specifically acetylated in vivo.
DNA-binding sites within the chromatin templates, and Future studies must involve the development of methin some cases, histone acetylation has been correlated ods to confirm the in vivo-acetylated lysine positions with increased levels of transcription (Van Lint et al., and to analyze the regulation of p53 acetylation by CBP/ 1996; Chen et al., 1997) . Hence, it has been proposed p300 in the cell. Interestingly, many deacetylase inhibithat transcriptional activation by sequence-specific actors, including sodium butyrate, trichostatin A, and trativators may involve recruitment and function of histone poxin, induce cell growth repression, transformation reacetyltransferases, while transcriptional repression by version, and apoptosis (Kijima et al., 1993; sequence-specific repressors may be mediated by the al., 1995; Buckley et al., 1996) . These phenotypes are recruitment of histone deacetylases (Pazin and Kadovery similar to the effects of p53 activation in the cell, naga, 1997). Consistent with this view, mutations of the making it interesting to find out whether these histone HAT domain have been shown to inactivate the coactivadeacetylase inhibitors can also inhibit p53 deacetylation tor function of GCN5 in yeast (Candau et al., 1997) . and whether some histone deacetylases can directly However, there is no direct evidence that histone acetydeacetylate p53.
lation and deacetylation events are either causally reIn addition, the proportion of the whole p53 protein lated to, or the exclusive function of, the cognate coactipopulation that is acetylated in normal cells and how vators and corepressors. the acetylation of p53 is regulated, particularly in re-
In support of the possibility of alternate functions for sponse to specific stimuli (e.g., UV), remain unknown. coactivators with acetyltransferase (or deacetylase) Since an antitumor agent, epoposide, can activate p53 activities is our demonstration that p300 has a potent and induce apoptosis in human testicular tumors by transcription factor acetyltransferase (FAT) activity in switching the latent form into an active form of p53 addition to the HAT activity, and that p300-mediated (Chresta and Hickman, 1996; Lutzker and Levine, 1996) , acetylation of p53 can dramatically increase the latent the present studies suggest that it may be useful to DNA-binding activity. The direct effect of the p300 FAT develop an activation strategy based on the stimulation function is clear, since the binding studies were done of p53 acetylation.
in vitro with recombinant proteins, and the observations that p53 is acetylated in vivo and that sequence-specific DNA binding of p53 is limiting for p53-mediated tranp300/CBP: HAT versus FAT Functions As first reported for the yeast coactivator GCN5 (Kuo et scriptional activation suggest that a similar p300 FAT function is operative in vivo. The possibility of cofactor al., 1996), mammalian coactivators p300/CBP (Bannister FAT activities is further supported by the observation be that acetylation by p300 leads to joint activator/ that other general transcriptional factors and cofactors coactivator recruitment to the promoter, both through can be acetylated by p300 in vitro (W. G. and R. G. R., enhanced p53 DNA-binding capability and through perunpublished data). sistent p53-p300 interactions, and that subsequent Our present study adds an important new perspective functions of both p300 (e.g., histone acetylation) and to our current understanding of the molecular mechap53 (e.g., TAF interactions) are then possible. nism of acetyltransferase/coactivator functions in tran-
In conclusion, we have provided an example of a nonscriptional activation by implicating a FAT function that histone regulatory protein, p53, which can be acetylated may operate in place of or, more likely, in addition to both in vitro and in vivo, and we have shown that acetylathe HAT function. Thus, acetyltransferase-containing tion of p53 by its coactivator p300 dramatically activates coactivators may be recruited by (interact with) seits biochemical function. This study clearly suggests a quence-specific activators for acetylation of either the potential pathway for activation of p53 in vivo and preactivators themselves (e.g., p53) or the general trandicts that other cellular regulatory proteins can be modiscription machinery (e.g., TFIIE, TFIIF, and PC4; W. G.
fied and functionally regulated in a similar manner. It and R. G. R., unpublished data), or both, with consefurther supports the views that protein acetylation and quent transcriptional activation. At the same time, the deacetylation are fundamental regulatory mechanisms recruitment of acetyltransferases to the promoter region in transcriptional regulation. could also induce local nucleosome modifications by histone acetylation, facilitating stable binding of the acti- and Thut et al., 1995) . Taken together, ) were transfected by calcium phosphate precipitation on a 10-cm plate essentially as previously described (Gu way. A speculative comprehensive model for p53 would et al., 1994) with minor modifications. p53 or p53⌬370 plasmids (5 Archer, T.K., Lefebvre, P., Wolford, R.G., and Hager, G.L. (1992) . Transcription factor loading on the MMTV promoter: a bimodal g) (Crook et al., 1994) mitogen responsive gene relies on a common nuclear factor. Nature mM NaCl, 1% Triton X-100, 0.2% Sarkosyl, 10% glycerol, 0.5 mM 370, 226-229. DTT, 1 mM NaF, 1 mM Na3VO4, 10 mM sodium butyrate, 0.5 g/ml Bannister, A.J., and Kouzarides, T. (1995) . CBP-induced stimulation leupeptin, 1 g/ml aprotinin, 1 g/ml pepstatin, and 0.5 mM PMSF).
of c-Fos activity is abrogated by E1a. EMBO J. 14, 4758-4762. The lysate was centrifuged twice at 17,000 g for 30 min at 4ЊC.
Bannister, A.J., and Kouzarides, T. (1996) . The CBP coactivator is Supernatants collected from 10 plates were immunoprecipitated a histone acetyltransferase. Nature 384, 641-643. with the indicated antibodies, which had been cross-linked to agarose beads, for 4 hr at 4ЊC. The beads were washed five times with Barak, Y.T., Juven, T., Haffner, R., and Oren, M. (1993). mdm2 ex-1 ml of lysis buffer. Immunopurified proteins were solubilized with pression is induced by wild type p53 activity. EMBO J. 12, 461-468. SDS-PAGE sample buffer and resolved on 10% SDS-PAGE gels.
Bhattacharya, S., Eckner, R., Grossman, S., Oldread, E., Arany, Z., Gels (1996) . Special HATs for special occaProteins were resolved on 10% SDS-PAGE gels, followed by semisions: linking histone acetylation to chromatin assembly and gene dry transfer to nitrocellulose members for 1 hr at room temperature.
activation. Curr. Opin. Genet. Dev. 6, 176-184. After incubation with the first antibody for 2 hr at room temperature, Buckbinder, L., Talbott, R., Velasco-Miguel, S., Takenaka, I., Faha, blots were subsequently incubated with secondary antibody and B., Seizinger, B.R., and Kley, N. (1995) . Induction of the growth visualized by ECL as suggested by the manufacturer (Amersham).
inhibitor IGF-binding protein 3 by p53. Nature 377, 646-649.
Electrophoretic Mobility Shift Assay
Buckley, A., Leff, M.A., Buckley, D.J., Magnuson, N.S., de Jong, G., EMSA was carried out essentially as described (Jayaraman and and Gout, P.W. (1996) . Alteration in pim-1 and c-myc expression Prives, 1995) with some modifications. Sequences of the oligonuassociated with sodium butyrate-induced growth factor dependency in autonomous rat Nb2 lymphoma cells. Cell Growth Differ. cleotides containing either wild-type or mutant p53 DNA-binding 7, 1713-1721. sequence are as follows: GADD45 wild type, TACAGAACATGTC TAAGCATGCTGGGG; GADD45 mutant, TACAGAATCGCTCTAAG Candau, R., Zhou, J.X., Allis, C.D., and Berger, S.L. (1997). Histone CATGCTGGGG. The DNA binding reactions (20 l) contained 20 acetyltransferase activity and interaction with ADA2 are critical for mM Tris-HCl (pH 7.5), 50 mM KCl, 5 mM MgCl2, 1 mM DTT, 0.5 mM GCN5 function in vivo. EMBO J. 16, 555-565. EDTA, 10% glycerol, 10 mM sodium butyrate, 0.5 mg/ml BSA, 100
Chakravarti, D., LaMorte, V.J., Nelson, M.C., Nakajima, T., Schulman, ng poly(dI-dC), and proteins as indicated. Reaction mixtures were I.G., Juguilon, H., Motminy, M., and Evans, R.M. (1996) . Roles of preincubated at room temperature for 20 min before a 32 P-labeled CBP/p300 in nuclear receptor signaling. Nature 383, 99-103. probe DNA (0.2 ng) was added and further incubated at room temChen, W.Y., Bailey, E.C., McCune, S.L., Dong, J-Y., and Townes, perature for 20 min. Each reaction mixture was then loaded onto a T.M. (1997) . Reaction of silenced, virally transduced genes by inhibinative 4% polyacrylamide gel (acrylamide:Bis, 50:1) containing 0.5 ϫ tors of histone deacetylase. Proc. Natl. Acad. Sci. USA 94, 5798-TBE and electrophoresed in 0.25 ϫ TBE at 180-220 V for 3 hr at 5803. 4ЊC. All procedures were basically the same for the analyses of Chiang, C.M., and Roeder, R.G. (1993) . Expression and purification activation of p53 DNA binding by synthetic peptides, except that of general transcriptional factors by Flag epitope-tagging and pepthe preincubation was performed at 30ЊC for 30 min before the tide elution. Peptide Res. 6, 62-64. probe was added. In the case of supershift assays, the indicated Chresta, C.M., and Hickman, J.A. (1996) . Oddball p53 in testicular monoclonal antibodies (200 ng) were added to reaction mixtures tumors. Nat. Med. 2, 745-746. during preincubation.
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